1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload.
Subcutaneous desferrioxamine, though effective in preventing or reducing iron overload in transfusion-dependent refractory anaemia, is expensive and inconvenient. One potentially cheaper and orally active alternative is 1,2-dimethyl-3-hydroxypyrid-4-one (L1). This drug has been tested in three multiply transfused patients with myelodysplasia. Gelatin capsules were taken at doses ranging from 0.5 g to 3.0 g. Urinary iron excretion increased substantially in all three patients and in the one tested was equal to that achieved with comparable doses of subcutaneous desferrioxamine. The amounts of iron excreted were related to the dose of L1 administered and the iron load of the patients. The urinary excretion of zinc, magnesium, and calcium did not increase, and the drug was well tolerated.
D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D002214:Capsules; D000077543:Deferiprone; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007501:Iron / Q000506:poisoning* / Q000652:urine; D007502:Iron Chelating Agents / Q000008:administration & dosage*; D008297:Male; D009436:Neural Tube Defects / Q000150:complications; D011728:Pyridones / Q000008:administration & dosage*
D002214:Capsules; D007502:Iron Chelating Agents; D011728:Pyridones; D000077543:Deferiprone; D007501:Iron